Jacobio Pharmaceuticals Group Co., Ltd. (77V)
Market Open
3 Aug, 10:31
XDUS 
€
0. 49
-0.01
-1.2195%
€
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
€ 0.49
Previous Close Want to track 77V and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
77V trading today lower at €0.49, a decrease of -1.2195% from yesterday's close, completing a monthly decrease of -3.7624% or -€0.02. Over the past 12 months, 77V stock lost -26.9173%.
77V is not paying dividends to its shareholders.
The last earnings report, released on Mar 25, 2026, exceeded the consensus estimates by 0.0111%. On average, the company has surpassed earnings expectations by 0.0074%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on HKEX (HKD).
77V Chart
Jacobio Pharmaceuticals Group Co., Ltd. (77V) FAQ
What is the stock price today?
The current price is €0.49.
On which exchange is it traded?
Jacobio Pharmaceuticals Group Co., Ltd. is listed on XDUS.
What is its stock symbol?
The ticker symbol is 77V.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Jacobio Pharmaceuticals Group Co., Ltd. ever had a stock split?
No, there has never been a stock split.
Jacobio Pharmaceuticals Group Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Yinxiang Wang CEO | XDUS Exchange | KYG4987A1094 ISIN |
| China Country | 301 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Jacobio Pharmaceuticals Group Co., Ltd. is an investment holding company focused on the pioneering discovery and development of innovative oncology therapies. Established in 2015 and operating from its headquarters in Beijing, China, Jacobio Pharmaceuticals is dedicated to advancing cancer treatments through its robust drug development programs. The company's approach combines targeted research with strategic collaborations, such as its license and partnership with AbbVie Ireland Unlimited Company, particularly in the area of SHP2 inhibitors, proving its commitment to tackling various forms of cancer with advanced therapeutic strategies.
Products and Services
- Glecirasib (JAB-21822): A KRAS G12C inhibitor involved in multiple stage studies targeting a range of solid tumors, including Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), and others.
- JAB-3068: An SHP2 inhibitor that has received approval from the FDA to enter clinical development, focusing on the treatment of esophageal cancer, including esophageal squamous cell carcinoma.
- JAB-3312: Another SHP2 inhibitor with applications in various cancer indications. This includes a Phase III pivotal study for KRAS G12C mutated NSCLC, a Phase I study for Osimertinib progressed NSCLC, and Phase IIa studies for NSCLC, Head and Neck Squamous Cell Carcinoma (HNSCC), and Esophageal Squamous Cell Carcinoma (ESCC).
- JAB-23E73: Currently under IND-enabling studies, this drug targets multiple KRAS mutants with implications for PDAC, CRC, and NSCLC.
- JAB-BX300: A self-developed LIF monoclonal antibody (mAb), under IND study aimed at treating solid tumors.
- JAB-22000: A small-molecule KRAS G12D inhibitor in the lead optimization study phase for the treatment of PDAC, CRC, and NSCLC.
- JAB-8263: A Bromodomain and Extra-Terminal motif (BET) inhibitor under Phase I studies, targeting Myelofibrosis (MF), Acute Myeloid Leukemia (AML), and solid tumors.
- JAB-2485: An Aurora Kinase A inhibitor under Phase I study, developed for the treatment of solid tumors.
- JAB-24114: This glutamine-utilizing enzyme inhibitor is under IND study for its potential in treating solid tumors.
- JAB-30355: An orally bioavailable small molecule activator under IND study, designed for patients with locally advanced or metastatic solid tumors.
Contact Information
Address: Building 8
Phone: 86 10 5631 5466
Website: https://www.jacobiopharma.com
